Sacubitril-Valsartan in Heart Failure Outcomes

Sacubitril-valsartan PARADIGM-HF mechanism outcomes

Mechanism

Sacubitril-valsartan (Entresto, formerly LCZ696) is a first-in-class angiotensin receptor–neprilysin inhibitor (ARNI) that works through two simultaneous and complementary pathways. Hubers & Brown 2016 The valsartan component blocks the AT1 receptor, suppressing the downstream effects of angiotensin II — vasoconstriction, aldosterone release, and pathological ventricular remodeling. The sacubitril component is a prodrug converted by esterases to its active form LBQ657, which inhibits neprilysin — the neutral endopeptidase primarily responsible for degrading natriuretic peptides (ANP, BNP) and other vasoactive peptides. Earl & Hankins 2016 Blocking neprilysin amplifies the natriuretic peptide system, producing vasodilation, natriuresis, diuresis, and antifibrotic/antiproliferative effects on the myocardium.

Critically, the reason sacubitril is paired with an ARB rather than an ACE inhibitor is safety: combining neprilysin inhibition with ACE inhibition markedly elevates bradykinin, causing serious angioedema. Pairing with an ARB provides RAAS suppression while keeping bradykinin accumulation manageable. Ferrari et al. 2015 Beyond natriuretic peptides, neprilysin inhibition also elevates bradykinin, substance P, and adrenomedullin — additional vasoactive substrates that may contribute to clinical benefit and are not fully accounted for by the BNP story alone. Singh et al. 2017

PARADIGM-HF Trial

PARADIGM-HF (NCT01035255) was an 8,442-patient randomized, double-blind, phase III trial in HFrEF patients (EF ≤40%), comparing sacubitril-valsartan 200 mg twice daily against enalapril 10 mg twice daily, on top of optimal background therapy (beta-blockers in 93%, mineralocorticoid antagonists in 56%). Bonow & Elguindy 2014 The trial was stopped early by the data safety monitoring board after a median follow-up of 27 months because of overwhelming benefit in the experimental arm.

The primary composite endpoint — cardiovascular death or first HF hospitalization — occurred in 21.8% of the sacubitril-valsartan group versus 26.5% with enalapril, a 20% relative risk reduction. Bonow & Elguindy 2014 +1 The individual components both contributed: CV death was reduced from 16.5% to 13.3%, and HF hospitalization was reduced by 21%. All-cause mortality fell from 19.8% to 17.0%, with a number needed to treat to prevent one death of about 35–36. Athyros et al. 2014 Symptom burden, assessed by KCCQ scores, also improved significantly.

Safety trade-offs were notable: hypotension and non-serious angioedema occurred more frequently with sacubitril-valsartan, while renal impairment, hyperkalemia, and cough were more common with enalapril. Bonow & Elguindy 2014 A mandatory run-in period excluded roughly 20% of enrolled patients who were intolerant of either drug, which means the trial population likely over-represents tolerant patients.

Downstream Evidence

A 2026 meta-analysis pooling three RCTs with over 18,000 participants (largely driven by PARADIGM-HF) confirmed a statistically significant 11% reduction in all-cause mortality vs. RAS inhibitors, with low heterogeneity. Das & Das 2026 Subgroup analyses of PARADIGM-HF show consistent benefit across sex — hazard ratios of 0.76 in women and 0.80 in men for the primary endpoint, with no significant interaction. Chimura et al. 2025

Beyond HFrEF, the PIONEER-HF trial showed that initiating sacubitril-valsartan in-hospital after acute HF decompensation produced a 44% reduction in HF rehospitalization versus enalapril. PARAGON-HF (HFpEF) narrowly missed its primary endpoint but found a favorable signal in patients with mid-range ejection fraction (EF 45–57%), and current guidelines suggest potential benefit in patients with EF in the lower half of the "preserved" range.

The trial evidence from my search gives a consistent picture: sacubitril-valsartan is genuinely superior to enalapril in HFrEF and has become a cornerstone of guideline-directed therapy, but results in HFpEF remain less definitive — a deeper search could surface more recent subgroup and real-world data.